IP Library › Granted Patent US 12,208,158
Granted Patent B2
US 12,208,158 · App. 17/510,271 · Granted Jan 28, 2025

Extended release of neuregulin for treating heart failure

Inventor: Mingdong Zhou (Shanghai, CN)
Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
A61K9/0019A61K38/1883
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,158
App. No.
17/510,271
Granted
Jan 28, 2025
Kind
B2
Abstract

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Claims (14)

1. A method for treating chronic heart failure in a patient, the method comprising administering subcutaneous extended release of neuregulin into the patient in an amount of 6 EU/kg/day to 60 EU/kg/day, wherein the neuregulin is administered into the patient through a pump, and wherein the chronic heart failure in the patient is classified as NYHA Class II or Class III.

2. The method of claim 1 , wherein the pump is a syringe pump.

3. The method of claim 2 , wherein the syringe pump is a mini pump.

4. The method of claim 3 , wherein the mini pump is an insulin pump.

5. The method of claim 1 , wherein neuregulin is in an amount of 24 EU/kg/day to 40 EU/kg/day.

6. The method of claim 1 , wherein neuregulin is in an amount of 24 EU/kg/day.

7. The method of claim 1 , wherein neuregulin is in an amount of 40 EU/kg/day.

8. The method of claim 1 , wherein the neuregulin is administered to the patient for an induction regimen.

9. The method of claim 8 , wherein the induction regimen includes an administration of neuregulin for at least 3, 5, 7, 10 or 15 consecutive days.

10. The method of claim 8 , wherein the induction regimen includes an administration of neuregulin for 10 consecutive days.

11. The method of claim 8 , wherein the neuregulin is administered for at least 2, 4, 6, 8, 10, 12, 16, 20, 24 consecutive hours every day.

12. The method of claim 8 , wherein the neuregulin is administered for 8 consecutive hours every day.

13. The method of claim 8 , wherein the neuregulin is administered to the patient for a maintenance regimen after the induction regimen.

14. The method of claim 13 , wherein the maintenance regimen includes an administration of neuregulin for at least 3 months, 6 months, 12 months, 5 years or even longer after the induction regimen.

Continuity (4)
Continuation 16126852 · Sep 10, 2018
Continuation 14892183
Provisional Application 61826433 · May 22, 2013
Related Publication 20220211613A1 · Jul 7, 2022
References Cited (210)
US 5530109A · Goodearl et al. · 1996 [cited by applicant]
US 5686102A · Gross et al. · 1997 [cited by applicant]
US 5716930A · Goodearl et al. · 1998 [cited by applicant]
US 5736154A · Fuisz · 1998 [cited by applicant]
US 5741511A · Lee et al. · 1998 [cited by applicant]
US 5834229A · Vandlen et al. · 1998 [cited by applicant]
US 5886039A · Kock et al. · 1999 [cited by applicant]
US 5941868A · Kaplan et al. · 1999 [cited by applicant]
US 6197801B1 · Lin · 2001 [cited by applicant]
US 6258374B1 · Friess et al. · 2001 [cited by applicant]
US 6589229B1 · Connelly et al. · 2003 [cited by applicant]
US 6750196B1 · Reh et al. · 2004 [cited by applicant]
US 7063961B2 · Ballinger et al. · 2006 [cited by applicant]
US 7115554B1 · Sklar et al. · 2006 [cited by applicant]
US 7226907B1 · Zhou · 2007 [cited by applicant]
US 7612164B2 · Zhou · 2009 [cited by applicant]
US 7686787B2 · Moberg et al. · 2010 [cited by applicant]
US 7795212B2 · Zhou · 2010 [cited by applicant]
US 7964555B2 · Zhou · 2011 [cited by applicant]
US 8394761B2 · Marchionni et al. · 2013 [cited by applicant]
US 8476405B2 · Zhou · 2013 [cited by applicant]
US 8609620B2 · Zhou · 2013 [cited by applicant]
US 8785387B2 · Zhou · 2014 [cited by applicant]
US 9012400B2 · Zhou · 2015 [cited by applicant]
US 9089524B2 · Zhou · 2015 [cited by applicant]
US 9198951B2 · Caggiano et al. · 2015 [cited by applicant]
US 9340597B2 · Zhou · 2016 [cited by applicant]
US 9434777B2 · Zhou · 2016 [cited by applicant]
US 9555076B2 · Zhou · 2017 [cited by applicant]
US 9580515B2 · Zhou · 2017 [cited by applicant]
US 9655949B2 · Zhou · 2017 [cited by applicant]
US 10098834B2 · Zhou · 2018 [cited by applicant]
US 10112983B2 · Zhou · 2018 [cited by applicant]
US 10441633B2 · Zhou · 2019 [cited by applicant]
US 10561709B2 · Zhou · 2020 [cited by applicant]
US 20040126860A1 · Epstein et al. · 2004 [cited by applicant]
US 20050065760A1 · Murtfeldt et al. · 2005 [cited by applicant]
US 20050277887A1 · Douglas et al. · 2005 [cited by applicant]
US 20060019888A1 · Zhou · 2006 [cited by applicant]
US 20060160062A1 · Young · 2006 [cited by applicant]
US 20060194734A1 · Zhou · 2006 [cited by applicant]
US 20060199767A1 · Zhou · 2006 [cited by applicant]
US 20070129296A1 · Zhou · 2007 [cited by applicant]
US 20070141548A1 · Kohl et al. · 2007 [cited by applicant]
US 20070190127A1 · Zhou · 2007 [cited by applicant]
US 20070213264A1 · Zhou · 2007 [cited by applicant]
US 20070264254A1 · Zhou · 2007 [cited by applicant]
US 20080260713A1 · Zhou · 2008 [cited by applicant]
US 20090156488A1 · Zhou · 2009 [cited by applicant]
US 20090203595A1 · Zhou · 2009 [cited by applicant]
US 20110135595A1 · Zhou · 2011 [cited by applicant]
US 20110229444A1 · Zhou · 2011 [cited by applicant]
US 20130078235A1 · Zhou · 2013 [cited by applicant]
US 20130196911A1 · Jay et al. · 2013 [cited by applicant]
US 20130259924A1 · Bancel et al. · 2013 [cited by applicant]
US 20140364366A1 · Zhou · 2014 [cited by applicant]
US 20150284440A1 · Zhou · 2015 [cited by applicant]
US 20160089329A1 · Zhou · 2016 [cited by applicant]
US 20160095903A1 · Zhou · 2016 [cited by applicant]
US 20160297859A1 · Zhou · 2016 [cited by applicant]
US 20160324876A1 · Zhou · 2016 [cited by applicant]
US 20170007671A1 · Zhou · 2017 [cited by applicant]
US 20170189489A1 · Zhou · 2017 [cited by applicant]
US 20170232068A1 · Zhou · 2017 [cited by applicant]
US 20170313784A1 · Zhou · 2017 [cited by applicant]
US 20170326204A1 · Zhou · 2017 [cited by applicant]
US 20170368140A1 · Zhou · 2017 [cited by applicant]
US 20180104311A1 · Zhou · 2018 [cited by applicant]
US 20190240145A1 · Zhou · 2019 [cited by applicant]
AU 6827894A · 1994 [cited by applicant]
CN 1276381A · 2000 [cited by applicant]
CN 1138785C · 2004 [cited by applicant]
CN 1498656A · 2004 [cited by applicant]
CN 1715926A · 2006 [cited by applicant]
CN 1743005A · 2006 [cited by applicant]
CN 1743006A · 2006 [cited by applicant]
CN 1768859A · 2006 [cited by applicant]
CN 1836731A · 2006 [cited by applicant]
CN 101310766A · 2008 [cited by applicant]
CN 101310779A · 2008 [cited by applicant]
CN 101394861A · 2009 [cited by applicant]
DE 3218121A1 · 1983 [cited by applicant]
EP 0036676A1 · 1981 [cited by applicant]
EP 0052322A2 · 1982 [cited by applicant]
EP 0058481A1 · 1982 [cited by applicant]
EP 0088046A2 · 1983 [cited by applicant]
EP 0102324A2 · 1984 [cited by applicant]
EP 0143949A1 · 1985 [cited by applicant]
EP 0133988A2 · 1995 [cited by applicant]
EP 0647449A1 · 1995 [cited by applicant]
EP 0142641A2 · 1995 [cited by applicant]
JP 60007934A · 1985 [cited by applicant]
JP A2005500025 · 2005 [cited by applicant]
RU 2180843C2 · 2002 [cited by applicant]
WO WO1989001489A · 1989 [cited by applicant]
WO WO1992018627 · 1992 [cited by applicant]
WO WO1994000140 · 1994 [cited by applicant]
WO WO199426298A1 · 1994 [cited by applicant]
WO WO1995032724 · 1995 [cited by applicant]
WO WO1996015812 · 1996 [cited by applicant]
WO WO1997009425A1 · 1997 [cited by applicant]
WO WO1999018976 · 1999 [cited by applicant]
WO WO2000037095A1 · 2000 [cited by applicant]
WO WO2000064400A2 · 2000 [cited by applicant]
WO WO2000078347A1 · 2000 [cited by applicant]
WO WO200164877A2 · 2001 [cited by applicant]
WO WO2001070307A1 · 2001 [cited by applicant]
WO WO200189568A1 · 2001 [cited by applicant]
WO WO2002040683A2 · 2002 [cited by applicant]
WO WO2002048191A2 · 2002 [cited by applicant]
WO WO2003035095A1 · 2003 [cited by applicant]
WO WO2003099300A1 · 2003 [cited by applicant]
WO WO2003099320A1 · 2003 [cited by applicant]
WO WO20030099321 · 2003 [cited by applicant]
WO WO2003099321A1 · 2003 [cited by applicant]
WO WO2004030716A2 · 2004 [cited by applicant]
WO WO2004030717A2 · 2004 [cited by applicant]
WO WO2004050894A2 · 2004 [cited by applicant]
WO WO2004112763A2 · 2004 [cited by applicant]
WO WO2006108208A1 · 2006 [cited by applicant]
WO WO2007062594A1 · 2007 [cited by applicant]
WO WO2007076701A1 · 2007 [cited by applicant]
WO WO2008028405A1 · 2008 [cited by applicant]
WO WO2009033373A1 · 2009 [cited by applicant]
WO WO2010060265A1 · 2010 [cited by applicant]
WO WO2010060266A1 · 2010 [cited by applicant]
WO WO2010142141A1 · 2010 [cited by applicant]
WO WO2011091723A1 · 2011 [cited by applicant]
WO WO2011112791A1 · 2011 [cited by applicant]
WO WO2011112864A1 · 2011 [cited by applicant]
WO WO2012012682A2 · 2012 [cited by applicant]
WO WO2013053201A1 · 2013 [cited by applicant]
WO WO2014056121A1 · 2014 [cited by applicant]
WO WO2014138502A1 · 2014 [cited by applicant]
WO WO2014187342A1 · 2014 [cited by applicant]
WO WO2015010449A1 · 2015 [cited by applicant]
WO WO2015101182A1 · 2015 [cited by applicant]
WO WO2016045493A1 · 2016 [cited by applicant]
WO WO2016058493A1 · 2016 [cited by applicant]
Bakalets, “Chronic heart deficiency with preserved left ventricle ejection fraction,” Problems of Health and Ecology, Gomel State Medical University, 3(33):7-11 (2012). English abstract. [cited by applicant]
Balligand et al., “Cardiac endothelium and tissue growth,” Prog Cardiovasc Dis., Jan.-Feb. 1997; 39(4):351- 360. [cited by applicant]
Britsch et al., “The ErbB2 and ErbB3 receptors sand their ligand, neregulin-1, are essential for development of the sympathetic nervous system,” Genes Dev., 12:1825-1836 (1998). [cited by applicant]
Buonanno et al., “Neuregulin and ErbB receptor signaling pathways in the nervous system,” Curr. Opin. Neurobiol., 11:287-296 (2001). [cited by applicant]
Carraway et al., “Neuregulin-2, a new ligand of ErbB/ErbB4-receptor tyrosine kinase,” Nature, 387:512-516 (1997). [cited by applicant]
Chang et al., “Ligands for ErbB-family receptors encoded by a neuregulin-like gene,” Nature, 387:509-512 (1997). [cited by applicant]
Chen et al., “Expression and Regulation of Cardiotrophin-1 in Ischemia-1 Reinfusion Cardiac Muscle of Rats and Effect of Neuregulin-1,” J. Appl. Clin. Pediatr., 21(1):29-52 (2006). [cited by applicant]
Chien et al., “Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response,” FASEB J., Dec. 1991; 5(15):3037-3046. [cited by applicant]
Chien, “Molecular advances in cardiovascular biology,” Science, 1993, 260(5110):916-917. [cited by applicant]
Colucci et al., “Pathphysiology of heart failure,” Chapter 13 in Heart Diseases: A textbook of cardiovascular medicine, Braunwald, ed., Saunders, Philadelphia. 1996; 5:394-420. [cited by applicant]
Corfas et al., “Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia,” Nature Neuroscience, 7(6):575-580 (2004). [cited by applicant]
Crone et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nat. Med., May 2002; 8(5):459-465. [cited by applicant]
Dias et al., “The molecular basis of skeletal muscle differentiation,” Semin Diagn Pathol., Feb. 1994; 11(1):3-14. [cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proc. Natl. Acad. Sci. U S A., Jun. 1985; 82(11):3688-3692. [cited by applicant]
Falls et al., “Neuregulins: functions, forms, and signaling strategies,” Exp. Cell Res., 284(1):14-30 (2003). [cited by applicant]
Fang et al., “Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism,” Chin. Med. J., 123:3597-3604 (2010). [cited by applicant]
Florini-JR. et al., “Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2,” J. Biol. Chem., May 31, 1996; 271(22):12699-12702. [cited by applicant]
Galindo et al., “Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure,” J. Am. Heart Assoc., 3(5):e000773 (2014). [cited by applicant]
Gao et al., “A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure,” J… [cited by applicant]
GENBANK Accession No. AJ247087, Apr. 15, 2005. [cited by applicant]
GENBANK Accession No. NM_001110810, Nov. 24, 2007. [cited by applicant]
Gu et al., “Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin,” Cardiovasc. Res., 88(2):334-343 (2010). [cited by applicant]
Guo et al., “Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia,” Brain Res., 1087:180-185, 2006. [cited by applicant]
Hein et al., “Altered expression of titin and contractile proteins in failing human myocardium,” J. Mol. Cell Cardiol., 26(10):1291-1306 (1994). [cited by applicant]
Hervent et al., “Left ventricular diastolic dysfunction in obese diabetic mice is attenuated by pharmacological inhibition of dipeptidyl peptidase IV,” Eur. J. Heart Failure Supplements, 12:S12-S16, Abstract 388, (2013). [cited by applicant]
Higashiyama et al., “A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4,” J. Biochem., 122:675-680 (1997). [cited by applicant]
Hijazi et al., “NRG-3 in human breast cancers: activation of multiple erbB family proteins,” Int. J. Oncol., 13:1061-1067 (1998). [cited by applicant]
Holmes et al., “Identification of heregulin, a specific activator of p185erbB2,” Science, 256:1205-1210 (1992). [cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proc. Natl. Acad. Sci. U S A., Jul. 1980; 77(7):4030-4034. [cited by applicant]
International Search Report from International Application No. PCT/CN03/00355, dated Jul. 3, 2003. [cited by applicant]
Izumo et al., “Calcineurin—the missing link in cardiac hypertrophy,” Nat. Med., 4(6):661-662 (1998). [cited by applicant]
Jabbour et al., “Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses,” Eur. J. Heart Fail., 13(1):83-92 … [cited by applicant]
Jones et al., “Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis,” J. Biol. Chem.,273(19):11667-11674 (1998). [cited by applicant]
Kuramochi et al., “Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling,” J. Biol. Chem., 279(49):51141-51147 (2004). [cited by applicant]
Langer et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J. Biomed. Mater. Res., Mar. 1981; 15(2):267-277. [cited by applicant]
Liu et al., “Effects of neuregulin on Rhesus monkey heart failure induced by rapid pacing,” Sichuan Da Xue Xue Bao Yi Xue Ban, 2009, 40(1):93-96 (in Chinese with English Abstract). [cited by applicant]
Liu et al., “Neuregulin-1/ErbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy,” J. Am. Coll. Cardiol., 2006, 48(7):1438-1447. [cited by applicant]
Luo et al., “Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4,” Proteins, 59(4):742-756 (2005). [cited by applicant]
Mahar et al., “Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-lik effects,” PLoS One, 6(10):e26610 (2011). [cited by applicant]
Mahmood et al., “Selection of the first-time dose in humans: comparison of different approacheds based on interspecies scaling of clearance,” J. Clin. Pharm., 43:692-697 (2003). [cited by applicant]
Massova et al., “Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding fee energies,” J. Am. Chem. Soc., 121(36):8133-8143 (1999). [cited by applicant]
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox,” In Merz and Le Grand (Eds.), The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495… [cited by applicant]
Notice of Allowability mailed Apr. 16, 2010 in U.S. Appl. No. 10/997,167. [cited by applicant]
Office Action mailed Dec. 22, 2008 in U.S. Appl. No. 10/997,167. [cited by applicant]
Office Action mailed Jun. 26, 2009 in U.S. Appl. No. 10/997,167. [cited by applicant]
Office Action mailed Mar. 7, 2008 in U.S. Appl. No. 10/997,167. [cited by applicant]
Office Action mailed Nov. 9, 2009 in U.S. Appl. No. 10/997,167. [cited by applicant]
Olson et al., “Regulation of muscle transcription by the MyoD family. The heart of the matter,” Circ. Res., 1993, 72(1):1-6. [cited by applicant]
Parker et al., “p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells,” Science, Feb. 17, 1995; 267(5200):1024-1027. [cited by applicant]
Pentassuglia et al., “The Role of Neuregulin 1β/ErbB signaling in the heart,” Exp. Cell Res., 315:627-637 (2009). [cited by applicant]
Physicians' Desk Reference. Medical Economics Data Production Co., Montvale, NJ. pp. 2314-2320 (1994). [cited by applicant]
Ramachandran et al., Vet. Pathol., 45:698-706 (2008). [cited by applicant]
Rumyantsev, “Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration,” Int. Rev. Cytol., 51:186-273 (1977). [cited by applicant]
Sadick et al., “Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput kinase receptor activation enzyme-linked immunosorbant assay,” Anal. Biochem., 235:207-214 (1996). [cited by applicant]
Sawyer et al., “Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity,” Circulation, 105(13)… [cited by applicant]
Schaper et al., “Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy,” Circulation, 83(2):504-514 (1991). [cited by applicant]
Shyu et al., Neurobio. Aging, vol. 25, pp. 935-944 (2004). [cited by applicant]
Sidman et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers, Jan. 1983; 22(1):547-556. [cited by applicant]
Simpson et al., “Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines,” Circ. Res., Dec. 1982; 51(6):787-801. [cited by applicant]
Slamon et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” N. Engl. J. Med., 344(11):783-792 (2001). [cited by applicant]
Stevenson et al., “Optimizing therapy for complex or refractory heart failure: a management algorithm,” Am. Heart J., 135(6 Pt 2 Su):S293-S309 (1998). [cited by applicant]
Swynghedauw, “Molecular mechanisms of myocardial remodeling,” Physiol. Rev., 79(1):215-262 (1999). [cited by applicant]
Takemura, Nihon Kyobu Geka Gakkai, pp. 247-253, 1993 (Abstract Only). [cited by applicant]
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry, estimating the maximum safe starting dose in initial clinical trials fo… [cited by applicant]
Wang et al., “Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure,” J. Geriatr. Cardiol., 9(2):172-179 (2012). [cited by applicant]
Wells, “Additivity of mutational effects in proteins,” Biochem., 29(37):8509-8517 (1990). [cited by applicant]
Yarden et al., “Untangling the ErbB signaling network,” Nat. Rev. Mol. Cell Biol., 2(2):127-137 (2001). [cited by applicant]
Yellon et al., “Myocardial Reperfusion Injury” N. Engl. J. Med., 357:1121-1135 (2007). [cited by applicant]
Zhao et al., “Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes,” Development, May 1998; 125(10):1899-1907. [cited by applicant]
Zhao et al., “Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes,” J. Biol. Chem., 273(17):10261-10269 (1998). [cited by applicant]
Zhou et al., “Retinoid-dependent pathways suppress myocardial cell hypertrophy,” Proc. Natl. Acad. Sci. U. S. A., Aug. 1, 1995; 92(16):7391-7395. [cited by applicant]